TD-HT073036

Nesvacumab(TD-HT073036) is a research-grade recombinant antibody targetingANG-2. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Human

IgG1-nd

Monoclonal

ANG-2, ANGPT2, Angiopoietin-2

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

O15123

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

REGN-910, 1296818-77-3

Trebananib (2xCon4C; AMG 386) is an Fc fusion peptibody that prevents Tie2 receptor activation through binding of both angiopoietin 1 (Ang1) and Ang2. Trebananib has anti-angiogenesis activity.• Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology., PMID:31108880• Acute respiratory distress syndrome., PMID:30872586• Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials., PMID:38158159• Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials., PMID:35085502• Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials., PMID:38280653• TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2., PMID:38382813• Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial., PMID:30905643• Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials., PMID:35085503• Blocking the angiopoietin-2-dependent integrin β-1 signaling axis abrogates small cell lung cancer invasion and metastasis., PMID:38775153• Loss of TGFβ-Mediated Repression of Angiopoietin-2 in Pericytes Underlies Germinal Matrix Hemorrhage Pathogenesis., PMID:39129597

SEC-HPLC detection for Research Grade Nesvacumab.　　|　Detects Human ANGPT2 in indirect ELISAs. ### Detects Human ANGPT2 in indirect ELISAs.　　|　SDS-PAGE for Research Grade Nesvacumab

For research use only. Not suitable for clinical or therapeutic use.